NR4A3 and acute myeloid leukemia: Because NR4A silencing is a molecular commonality between AML patients with different myeloid malignancies, and because overexpression of NR4A1 or NR4A3 in murine leukemic bone marrow cells or human AML cell lines has desirable effects, it is possibly a valid pharmacological target to treat AML.